ReShape Lifesciences (RSLS) reported a modest Q4 2023 with revenue of $1.982 million and a GAAP net loss of $1.698 million, underscoring the ongoing revenue headwinds from GLP-1 prescriptions that continue to compress near-term top-line opportunities. The company highlighted a strategic pivot toward aggressive cost reductions intended to extend cash runway and accelerate profitability through the full U.S. rollout of the Lap-Band 2.0 FLEX. Management underscored that 2024 operating expense reductions are targeted at approximately $8 million, or more than 50% versus 2023 (excluding one-time costs), as part of a broader path to sustainable profitability. Concurrently, RSLS signaled continued investment in growth drivers and commercialization capabilities, including digital lead generation via Hive Medical and an expanded marketing effort around Lap-Band 2.0 FLEX, while pausing non-core programs such as ReShapeCare to reallocate resources.
On a full-year basis, 2023 revenue totaled $8.7 million, down from 2022 by about $2.6 million, with gross profit of $5.5 million and gross margin of roughly 64%. Despite the top-line decline, management emphasized margin improvements driven by reallocation of inventory costs away from inventory-heavy activities toward other projects in 2023. Non-GAAP adjusted EBITDA for 2023 was reported as $13.6 million versus a $23 million loss in the prior year, highlighting a meaningful operational efficiency program that supports a lower cost base going into 2024. The company remains cash and debt-free, ending 2023 with approximately $4.56 million in cash, and a net debt position of about negative $4.30 million. These factors, together with a limited but positive early reception to Lap-Band 2.0 FLEX (and its PMA supplement approval), position RSLS for a potential revenue inflection in 2024 if the limited U.S. rollout gains traction.
The investment narrative rests on three pillars: (1) aggressive cost discipline to preserve cash and reallocate resources toward profitable growth initiatives; (2) expansion of the Lap-Band franchise via the 2.0 FLEX upgrade and broader commercialization; and (3) pursuing strategic partnerships and M&A opportunities to broaden the product portfolio and distribution footprint. Investors should monitor the pace of Lap-Band 2.0 FLEX adoption, the cadence of U.S. market penetration in 2024, competitive dynamics in obesity management, and the company’s ability to translate margin improvements into sustainable profitability.